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Una-Jovana V. Vajić a, Djurdjica M. Jovović a 
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A B S T R A C T   
Lifestyle modifications such as increase in high-fat food consumption importantly increases the risks for car-
diovascular disease. The principal objective of this study is to analyze effects of different high fat diet (HFD) 
sources on haemodynamic parameters, lipid and oxidative profile, myeloperoxidase activity, and markers of 
inflammation (IL-6/pentraxin-3). HFD containing 20% of fat, provided by lard (saturated) or soybean oil (un-
saturated), as well as control diet were administering to three groups (L, SO and C). Food efficiency ratio and 
plasma lipids were significantly elevated in both HFD groups. However, only SO group showed an increase in 
systolic arterial pressure, oxidative stress index, myeloperoxidase activity, liver lipids as well as markers of 
inflammation: IL-6 and pentraxin-3 (PTX3). In summary, these results indicate inflammogenic potential of 
excessive soybean oil consumption in triggering liver damage.   
1. Introduction 
Cardiovascular diseases (CVD) are a major cause of death and 
disability worldwide [1], and they are a great extent result of unbal-
anced diets and physical inactivity. Numerous studies in the 1950s and 
1960s showed positive correlation among dietary saturated fatty acids 
intake (SFAs) and the risk of cardiovascular disease [2], thus SFAs 
deemed unhealthy. SFAs are often found in high-fat types of meats and 
dairy products, such as fatty beef, lard, sausage, cream, butter, and 
cheese. These types of fats are nominated as “bad” kind of fat that raise 
cholesterol levels in the blood and increase the risk of cardiovascular 
diseases [3,4]. 
Soybean oil, as a source of unsaturated fatty acids (UFAs), is the 
second largest source of vegetable oil, commonly used for making 
mayonnaise, salad dressing, margarine, and nondairy coffee creamers 
[5]. It is also a mainstay ingredient in many processed foods throughout 
the baking, bread-making, cooking, and supermarket supply industries, 
or for extensive use in the restaurants, hotels, cafeterias, and multiple 
fast food industry. Soybean oil is derived from soybean seed and has 
50% linoleic acid, polyunsaturated omega-6 fatty acid (n-6 PUFAs), 20% 
oleic acid, monounsaturated omega-9 fatty acid (n-9 MUFAs) [6], and 
8% linolenic acids. Dietary oils are one of main sources of essential fatty 
acids in the human body, actually, linoleic acid is one of two essential 
fatty acids for humans, who must obtain it through ingestion. Linoleic 
and linolenic acids are also precursors of hormones that regulate smooth 
muscle contraction, arterial blood pressure, and the growth of healthy 
cells [7]. 1 
Fatty acids, the building blocks of the fat/oil, are bioactive 
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compounds involved in numerous homeostatic processes including 
metabolism. However, excessive consumption of some fatty acids, pri-
marily SFAs, results in health hazards. Randomized controlled trials and 
prospective studies provide strong evidence that replacing SFAs by UFAs 
reduced serum cholesterol and LDL-C [8,9]. According to these in-
vestigations, nutritional guidelines encouraged people to reduce their 
intake of SFAs, typically found in foods from animal origin and other-
wise, increase intake of UFAs found in plant oils [10], such as those 
found in soybean oil [7]. This recommendation has begun to apply in the 
food industry, and in the last two decade the soybean oil has been 
becoming the main oil in food industry. The relation between risk of 
CVD and high intake of UFAs, like linoleic and oleic acid, the main 
components of soybean oil, has been less extensively studied. The results 
of the previous study showed that only 14 days of 20% soybean oil 
supplemented diet could help in reducing the risk of hyperlipidemia and 
atherosclerosis [7]. Therefore, the question is could the long-term use of 
high doses of soybean oil possibly be unsafe. 
One of the main factor that favor nutritional oxidative stress is an 
excessive consumption of fat. By literature data, it is well known that in 
conditions of continuous high-fat intake degree of faty acids saturation 
might have a crucial role in the development of hyperlipidemia and 
nutritional oxidative stress, trough reactive oxygen species formation in 
vascular cells [11]. A high fat diet also reduced activity of liver Nrf2, a 
controller of the antioxidant enzymes activity, which is related to the 
high production of the free radicals and consequent lipid and protein 
oxidation in the liver [12]. Accumulation of lipid metabolites generates 
harmful intracellular substrates which in molecular pathway induce 
vascular hypertrophy, interstitial fibrosis, and apoptosis [13]. Thus, 
during lipid peroxidation produced free radicals induce oxidative 
damages of proteins and DNA and cause cellular damage, hypertrophy, 
and remodeling [14]. Advanced oxidation protein products (AOPP) are 
capable to induce releasing of inflammatory mediators and thus repre-
sent a new class of inflammatory mediators and markers of oxidative 
stress [15]. According to the literature, increasing in HDL-C is associated 
with a CVD protection [16], but when anti-oxidant and 
anti-inflammatory functions of HDL-C are overwhelmed by pathological 
processes, such as inflammation, HDL-C is converted into a ‘dysfunc-
tional’ pro-inflammatory particle [17]. 
Additional dates conforming that myeloperoxidase (MPO), heme- 
containing enzyme that catalyzes the hydrogen peroxidase-mediated 
oxidation of halide ions to hypochlorous acid, stimulates the proin-
flammatory response by releasing cytokines such as IL-1 and IL-6 [18]. 
The role of IL-6 in the liver pathology is very complex. It activates 
several type of cells, such as immune cells, hepatocytes, hematopoietic 
stem cells, etc. Furthermore, it is one of the mediators that contributes to 
non-alcoholic fatty liver disease [19], and one of the most common 
causes of abnormal liver function. Finally, these processes result in 
chronic liver injury that is characterized by the accumulation of large 
triglyceride droplets within hepatocytes and massive steatosis of the 
liver [20]. In addition, IL-6 was known to induce the liver to synthesize a 
group of proteins called acute phase proteins [19], among which is 
pentraxin-3 (PTX3), a member of the humoral immune molecules 
released locally at the site of injury [21]. To date, PTX3 levels were 
usually investigated by the research studies in assessment of CVD [22, 
23]. However, the level and role of PTX3 in liver injury and in response 
to inflammation are not well understood. 
Therefore, this work addresses the hypothesis that fats from different 
sources (animals/plants) cause similar degree of oxidative damage in 
both cellular proteins and lipids that correlates with similarly alteration 
in haemodynamic and inflammatory responses, with special reference to 
link between pentraxin-3 and myeloperoxidase activity in normotensive 
Wistar rats. 
2. Material and methods 
2.1. Animals 
The experimental protocol was in accordance with the National Law 
of AnimalWelfare (“Sl.gl.RS” 41/09 and 39/10) and the Directive 2010/ 
63/EU. The study protocol was approved by the Ethic Committee of the 
Institute for Medical Research (IMR), University of Belgrade, Serbia and 
Veterinary Directorate, Ministry of Agriculture and Environmental 
Protection, Republic of Serbia (No. 323-07-06069/2015-05). Protocols 
were performed on 5-month-old male Wistar rats (200–250 g), bred at 
IMR. Experimental animals were housed in groups of four in plastic 
cages (Macrolon® cage type 4, Bioscape, Germany) with sawdust 
bedding (Versele-Laga, Belgium) certificated as having contaminant 
levels below toxic concentrations. Environmental conditions were 
controlled and monitored by a central computer assisted system with a 
temperature of 22 ± 2 ◦C, relative humidity of 55 ± 15%, 15–20 air 
changes/h, and artificial lighting of approximately 220 V (12 h light/ 
dark cycle). Experimental animals had free access to tap water from 
municipal mains, filtered through 1.0 µm filter (Skala Green, Serbia). 
The animals were randomly divided into three groups (n = 8 rats in 
each group) and were feading for 8 weeks. Control group (C) received 
normal-fat diet consisted of commercial chow for laboratory rats 
(“Veterinarski zavod” Subotica, Serbia). HFD groups received standard 
chow for laboratory rats enriched with lard (L) or soyabean oil (SO) at 
20% of the total mass chow (Institute of food tehnology, University of 
Novi Sad, Serbia) (Table 1). 
Diets were prepared weekly to minimize external oxidation of lipids. 
Body weight and food intake were monitored once per week. At the end 
of the experiment, the body weight impact of diverse diets was evalu-
ated by calculating the cumulative weight gain and food efficiency ratio 
of the rats, food intake and calorie intake, as described by Machaba et al. 
[24]. 
2.2. Haemodynamic measurements 
Haemodynamic measurements were performed at the end of the 
diets. Systolic (SAP) and diastolic arterial pressure (DAP) were measured 
directly in anaesthetized rats (sodium pentobarbital 35 mg/kg i.p.), 
through a femoral artery catheter (PE-50, Clay-Adams Parsippany, NJ, 
Table 1 
Diet ingredients and composition.   
NFD HFD 
L SO 
Ingredients (%)       
Protein  20  20  20 
Cellulose  5  5  5 
Fat  4  4  4 
Calcium  1  1  1 
Lysine  0.90  0.90  0.90 
Methionine+cystine  0.75  0.75  0.75 
Phosphor  0.50  0.50  0.50 
Sodium  0.20  0.20  0.20 
Lard  0  20  0 
Soybean oil  0  0  20 
Composition (mg/kg)       
Zinc  100  100  100 
Iron  100  100  100 
Manganese  30  30  30 
Copper  20  20  20 
Iodine  0.5  0.5  0.5 
Selen  0.1  0.1  0.1 
Vitamin A (IJ/kg)  10,000  10,000  10,000 
Vitamin D (IJ/kg)  1600  1600  1600 
Vitamin E (mg/kg)  0.5  0.5  0.5 
Vitamin B12 (mg/kg)  0.02  0.02  0.02 
NFD, normal (standard) diet; HFD, high-fat diet; L, lard; SO, soybean oil. 
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USA) connected to physiological data acquisition system (9800TCR 
Cardiomax III-TCR Thermodilution Cardiac Output, Columbus In-
struments’, Columbus, OH, USA). A jugular vein was cannulated with 
polyethylene tubing PE-50 for the injection of cold saline. Further, the 
left carotid artery was cannulated with PE-50 tubing and attached to a 
Cardiomax III thermo sensor for the determination of cardiac output 
(CO). The second Cardiomax III thermocouple sensor was placed in cold 
saline. Following 20 min for stabilization after surgery, cold saline (0.2 
ml) was injected through the jugular vein and mean arterial pressure 
(MAP) and CO were recorded. Total peripheral vascular resistance 
(TPVR) was calculated by dividing MAP with CO normalized for body 
weight and expressed as mmHg x min x kg/ml. 
2.3. Biochemical measurements 
Biochemical parameters were determined after haemodynamic 
measurements and blood sample collection. Blood was collected by 
punctation of the abdominal aorta, poured in a tube containing lithium 
heparin (Li-heparin, Sigma, USA), and centrifuged at 4000 rpm at 4 ◦C, 
20 min. After blood sample collection all animals were sacrificed by 
pentobarbital overdose injection. Plasma was collected and stored at −
20 ◦C until assaying. Livers were harvested, weighted, and stored at −
70 ◦C for later analysis. Alanine aminotransferase (ALTL), aspartate 
transaminase (ASTL), lactate dehydrogenase (LDHI), uric acid (UA) 
plasma levels and total cholesterol (TC), high density lipoprotein 
cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), tri-
glyceride (TG), were determined in plasma and liver samples using 
commercial kits for automatic analyzer Cobas Integra 400 (Hoffmann-La 
Roche, Germany). Triglyceride concentration in the liver is presented as 
mg of triglyceride/g of the liver tissue. Non-HDL (atherogenic choles-
terol) was calculated according to the following equation: non- 
HDL=LDL-C+VLDL-C [25]. The atherogenic index of plasma (AIP) was 
calculated according to the following equation: AIP=
(LDL-C+VLDL-C)/HDL-C, with units for LDL-C and HDL-C in mmol/L 
[26]. 
2.4. Evaluation of systemic and liver redox state 
Plasma total antioxidant capacity (TAC) method is based on the 
bleaching of characteristic color of a more stable ABTS [2,2’-azinobis (3- 
ethylbenzothiazoline-6-sulfonic acid)] radical cation by antioxidant 
sample constituents [27]. Total peroxide concentration (TOS) of plasma 
is based on the oxidation of ferrous iron to ferric iron by the various 
types of peroxides contained in the plasma samples, in the presence of 
xylenol orange which produces a colored ferric-xylenol orange complex 
whose absorbance can be measured spectrophotometrically, [28]. Ratio 
of total peroxide to TAC levels was accepted as oxidative stress index 
(OSI) and expressed in arbitrary units. 
In order to determine the level of lipid peroxidation, we measured 
plasma and liver thiobarbituric acid reactive substances (TBARS) ac-
cording to the method of Ohkawa et al. [29] using 4,6-Dihydroxy-2-mer-
captopyrimidine. Plasma and liver advanced oxidation protein products 
(AOPP) were measured in acidic condition in the presence of potassium 
iodide [30]. Concentration of nitrites (NO2- ) was measured in plasma by 
the Griess reagent method as previously described [31]. The concen-
tration of superoxide anion radical (O2− ) in plasma was measured at 530 
nm, after the reaction of nitro blue tetrazolium in TRIS buffer [32]. 
Paraxonase activity (PON1) in plasma was evaluated by phenyl ac-
etate [33]. Determination of prooxidant-antioxidant balance (PAB) in 
liver tissue was performed using 3,3′, 5,5′-tetramethylbenzidine as a 
chromogen [34]. The activities of antioxidant enzymes: superoxide 
dismutase (SOD) and catalase (CAT) were measured in liver homoge-
nates by the spectrophotometric method, as previously described [35, 
36]. Myeloperoxidase enzyme activity in plasma and liver samples was 
determined by o-dianisidine-H2O2 method as described by Kothari et al. 
[18]. 
2.5. Inflammatory markers of liver tissue 
Quantitative determinations of IL-6 and PTX3 in liver homogenate 
were performed by rat-specific ELISA kits (IL-6 and PTX3: Elabscience 
Biotechnology inc., Houston, USA). Previously frozen liver tissue were 
processed in accordance with the manufacturer’s recommendations. 
Briefly, liver tissue were dissolved with phosphate buffer, and stored at 
− 20 ◦C for 30 min. After three freeze-thaw cycles to break up the cell 
membranes, lysates were centrifuged at 10,000 rpm, 4 ◦C for 5 min. The 
supernatant was further assayed, and values were expressed as ng/ml. 
All samples were measured in triplicate in a single assay according to the 
manufacturers’ instructions. For IL-6 and PTX3 detection, the sensitivity 
of the system was 7.5 pg/ml and 0.4 ng/ml, and the intra- and interassay 
coefficients of variation of 3 samples with low, mid range and high level 
were 5.9, 4.83, 5.03% and 5.09, 5, 4.9%, respectively. 
2.6. Statistical analysis 
Results are expressed as mean ± SD. One-way analysis of variance 
(ANOVA) was applied as appropriate. Fisher LSD test was performed as a 
post hoc multiple comparison test (Statistica 8). The Pearson correlation 
between the examined parameters was also determined. P-value < 0.05 
was considered significant. 
3. Results 
3.1. Body weight and food intake 
The body weight increased significantly during the experimental 
period in all groups (p < 0.001), but there were no significant differ-
ences in mean of weights after the intervention period between the 
groups (Fig. 1A). Food intake in the groups of rats treated with HFD (L or 
SO) was significantly lower compared to standard food (Fig. 1B). Con-
cerning the food efficiency ratio, L and SO groups had a significant in-
crease compared to control (Fig. 1C; p < 0.001). It was followed by 
significantly increased calorie intake in both HFD groups (Fig. 1D). 
3.2. Haemodynamic results 
Soybean oil feeding caused a significant increase in SAP compared to 
the standard diet (Fig. 2A). DAP was significantly increased after 8 week 
consumption in both lard (p < 0.05) and soybean oil (p < 0.01) groups 
compared to control group (Fig. 2B). On the other side, both HFD did not 
significantly change cardiac output and total vascular resistance 
(Fig. 2C.D). 
3.3. Biochemical results in plasma 
Plasma total cholesterol was significantly higher in the groups 
receiving L or SO compared to C group (Fig. 3A.; p < 0.001; p < 0.01; 
respectively), while there were no significant changes in triglyceride 
levels (data no show). In similar way, LDL-C, non-HDL (Fig. 3B. D.; 
p < 0.001), as well as the atherogenic index were increased (Fig. 3E.; 
p < 0.05). In relation to HDL-C, groups that were on lard or soybean oil 
diets showed higher values than group on standard diet (Fig. 3C.; 
p < 0.001; p < 0.01; respectively). Plasma ALTL was significantly 
increased in both high-fat diet groups (Fig. 3G. p < 0.05). On the other 
side, ASTL and LDHI2 were significantly higher only in SO group 
compared to control group (Fig. 3H.I; p < 0.05). 
Plasma TBARS was significantly increased in L and SO groups, 
compared to control group (Fig. 4A. p < 0.01; p < 0.05; respectively), 
followed by significantly higher plasma AOPP in both high-fat diet 
groups (Fig. 4B.; p < 0.001). More interesting was that 8 weeks con-
sumation of enriched SO diet was statistically decreased TAC (Fig. 4E., 
p < 0.01) while TOS and OSI levels were significantly higher compared 
to standard diet (Fig. 4D.F; p < 0.05; respectively). The highest level of 
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Fig. 1. Body weight (A), food intake (B), food efficiency ratio (C), and calorie intake (D) of rats assigned to different diet. C-control, L-lard, SO-soybean oil group. 
Values are means ± SD; * ** , * *, * indicate p < 0.001, 0.01, 0.05. 
Fig. 2. Systolic arterial pressure (A), diastolic arterial pressure (B), cardiac output (C) and total vascular resistance (D) in experimental groups. C-control, L-lard, SO- 
soybean oil group.Values are means ± SD; * *, * indicate p < 0.01, 0.05. 
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O2− and NO2− were noticed in SO group (Fig. 4G.H. p < 0.001; p < 0.05; 
respectively). Level of UA was significant 1.7-fold increased, as well as 
the activity of MPO which was even four times increased, only in SO 
group compared with C group (Fig. 4C. I. p < 0.001; p < 0.01; 
respectively). 
3.4. Lipid status in the liver tissue 
Compared with the control diet, the SO diet significantly increased 
liver lipids: total cholesterol, triglyceride, LDL-C, and non-HDL (Fig. 5A. 
B.D.E. p < 0.01; p < 0.001; p < 0.05; p < 0.01; respectively) that im-
plies serious steatosis of the liver. Liver triglycerides content ranging 
from 6.57% to 21.81% among groups. 
3.5. Redox status in the liver tissue 
Fig. 6. shows the redox state in liver tissue. AOPP levels were 
significantly higher in both high-fat diet groups, while TBARS was 
significantly higher only in SO group (Fig. 6A.B. p < 0.001; p < 0.01; 
respectively). On the other hand, the most significant differences in PAB, 
as well as MPO activity were observed only in SO group (Fig. 6C.D. 
p < 0.001; p < 0.001 respectively). The similar trend was maintained in 
both superoxide dismutase (SOD) and catalase (CAT) activity (Fig. 6E.F. 
p < 0.01; p < 0.001; respectively). 
3.6. Markers of inflammation in the liver tissue 
Cytokines implicated in inflammatory pathways, IL-6 and PTX3 in 
the liver tissue, were significantly increased in SO group in comparison 
to both C and L groups (Fig. 7A.B). In SO group, IL-6 levels remained 
significant with approximately 1.7-fold and 2-fold difference compared 
to C and L group, (p < 0.01; p < 0.001 respectively). In the same group, 
the level of PTX3 increase 6.5-fold compared to C group and 4.9-fold 
compared to L group (p < 0.001). 
3.7. Correlation 
We found significant correlations between HDL-C function (charac-
terized by PON1 and MPO activities), PAB, and the levels of inflam-
matory biomarkers IL-6 and PTX3 measured in liver. Namely, plasma 
PON activity was in high negative correlation with both plasma and liver 
MPO activities, as well as with the expressions of IL-6 and PTX3, while 
MPO activity either in plasma or liver tissue markedly and positively 
correlate with the levels of IL-6 and PTX3 (Table 2). 
4. Discussion 
The present study examined whether diets varying in faty acids 
composition could differentially affect the rate of body weight gain, lipid 
and oxidative status, as well as the inflammatory response. We 
demonstrated that both HFD, despite the reduced food intake, increased 
calorie intake and compromised plasma lipid profile. The lower food 
Fig. 3. Biochemical results: TC/total cholesterol (A); LDL-C/low density lipopropein cholesterol (B), HDL-C/high density lipoprotein cholesterol (C), non-HDL 
cholesterol (D), atherogenic index (E), PON1/paraoxonase 1 (F), ALTL/alanine aminotransferase (G), ASTL/aspartate transaminase (H), LDHI/lactate dehydroge-
nase (I) in experimental groups. C-control, L-lard, SO-soybean oil group.Values are means ± SD; * ** , * *, * indicate p < 0.001, 0.01, 0.05. 
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consumption in both high-fat diet (vs. controls) equalled out caloric 
intake between all groups, which resulted in similar final body weights. 
These data agree with previous experiments that high calorie intake was 
enough to cause a smaller food consumption [37]. Besides, our results 
show that, in normotensive Wistar rats, only consumption of food 
enriched with soyabean oil increased systolic blood pressure, disrupted 
plasma/liver oxidative stability which was closely related to enhanced 
plasma/liver MPO activity, and liver inflammation confirmed by 
elevated IL-6 and PTX3 expressions. 
Much research around the world has shown that the replacement of 
saturated fats with reasonable amounts of polyunsaturated fats, such as 
those found in soybean oil, is recommended [8,9]. Also, Uhegbu et al. 
showed that soybean oil diet 10%, 20% and 30%, respectively for 14 
days can help in reducing the risk of hyperlipidemia and atherosclerosis 
[7]. Our results clearly show that both 20% of L and SO diets after 28 
days supplementation significantly increased total plasma cholesterol 
and LDL-C levels, as well as the atherogenic index, compared to the 
regular diet. Hence, an essential question in our study is why the SO diet, 
rich in UFAs, causes a disorder of the lipid profile, especially when 
epidemiological and basic research suggest otherwise. Namely, Shen 
et al. [38] showed that in human population 12 week treatment with 
soybean capsule, which contains 910 mg of soybean oil, inhibited 
cholesterol absorption and lowered LDL-C levels. Soybean oil contains 
linolenic, linoleic, and oleic acid, which have different cholesterol and 
LDL-C lowering effects [7]. Also, some studies have documented that 
higher intake of linoleic acid reduces LDL-C [39] and reduces the risk of 
hypertension [40]. On the other hand, it was shown that diet with 
increasing doses of unsaturated linoleic acids (110–1100 mg/kg/day) 
significantly increase total cholesterol in rats after 11 week treatment 
[41]. Also, Syrian hamsters fed 6 weeks with the HFD containing 14% 
soybean oil showed significantly higher TG, TC, LDL-C, and HDL-C in 
serum compared with animals on low-fat basal diet [42]. Such contra-
dictory results might be explained by the fact that increase in the intake 
of linoleic acid increases the linoleic acid content in very-low-density 
lipoproteins (VLDL), which increase their susceptibility to oxidize. 
Indeed, linoleic acid is the most common oxidized fatty acid in LDL 
particules. Once linoleic acid becomes oxidized in LDL, aldehydes and 
ketones covalently bind apolipoprotein B, creating unrecognizable LDL 
for the LDL receptors in the liver, but is now recognized by scavenger 
receptors on macrophages leading to the classic foam cell formation and 
atherosclerosis [43]. 
A fat enriched diet and excessive calorie intake among the environ-
mental factors are known to increase incidence of metabolic disorders 
such as hyperlipidemia, diabetes, hypertension, obesity, and cancer 
[44]. In our study, the excessive consumption of L or SO resulted in 
extensive lipid and protein oxidations (significant increase in plasma 
TBARS and AOPP levels) that could be associated with the occurrence of 
vascular remodeling, as indicated by an elevated atherogenic index. 
These findings are in accordance with recent evidences in rodents 
showing induced elevation of lipid peroxidation [45] and AOPP accu-
mulation [46] with controversial results regarding the level of NO me-
tabolites in different organs or tissues [45]. 
In the present study, both HFD, L, and SO increase HDL-C compared 
to the regular rat food. However, there is a question about HDL-C 
Fig. 4. TBARS/thiobarbituric acid reactive substances (A), AOPP/advanced oxidation protein products (B), UA/uric acid (C), TOS/total oxidant status (D), TAC/total 
antioxidant capacity (E), OSI-oxidative stress index (F), O2− / superoxide anion radical (G), NO2- / nitrites (H) and MPO/myeloperoxidase enzyme activity (F) of plasma 
in experimental groups. C-control, L-lard, SO-soybean oil group.Values are means ± SD; * ** , * *, * indicate p < 0.001, 0.01, 0.05. 
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functionality. Functional HDL-C have potent antioxidant properties, as 
well as anti-inflammatory, antithrombotic, cytoprotective, vasodilatory 
activity. This wide spectrum of biological activities likely reflects the 
heterogeneity of HDL-C particles, and proteomic analysis showed about 
48 plasma circulate proteins, including: lecithin-cholesterol acyl-
transferase, phospholipid transfer protein, paraoxonase, and 
acetylhydrolase which could modulate HDL-C and convert it to HDL-C 
ester [47,48]. This can induce varying degrees of HDL-C dysfunction 
reflected in impaired reverse cholesterol transport and resulting in high 
plasma levels of a dysfunctional free cholesterol-rich HDL-C. Finally, 
such increasing of plasma cholesterol bioavailability produces 
whole-body hypercholesterolemia [49]. Someone studies indicate that 
Fig. 5. Liver lipid status: total cholesterol (A), triglyceride (B), triglyceride concentration (C), HDL-C/high density lipoprotein cholesterol (D), non-HDL (E), LDL-C/ 
low density lipopropein cholesterol (F) in experimental groups. C-control, L-lard, SO-soybean oil group.Values are means ± SD; * ** , * *, * indicate p < 0.001, 
0.01, 0.05. 
Fig. 6. Redox status in liver tissue: TBARS/thiobarbituric acid reactive substances (A), AOPP/advanced oxidation protein products (B), PBS/ prooxidant-antioxidant 
balance (C), MPO/myeloperoxidase enzyme activity (D), SOD/superoxide dismutase (E) and CAT/catalase (F) in experimental groups. C-control, L-lard, SO-soybean 
oil group.Values are means ± SD; * ** , * * indicate p < 0.001, 0.01. 
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the HDL-C from patients with CVD does not have a protective action, but 
does stimulate inflammation and free radical synthesis [17,48]. Also, 
prospective studies in human population showed that very high plasma 
HDL-C levels, as well as very large HDL-C particles were associated with 
higher risk for CVD [50]. This data suggests that HDL-C, commonly 
recognized as protective in some circumstances, becomes 
pro-atherogenic and dysfunctional. Dysfunctional HDL-C is followed by 
decreased level and activity of anti-inflammatory/anti-oxidative PON1, 
an essential collaborator of HDL-C protection against of LDL-C [51]. On 
the other hand, in vitro studies have demonstrated that oxidized lipo-
proteins, like LDL-C, contribute to HDL-C dysfunctionality through 
decreasing of PON1 activity [52]. Considering literature data in human 
population, the plasma PON1 activity markedly decreases in response to 
a diet rich in trans fatty acids [53], as well as that high-cholesterol diet in 
rabbits reduced PON1 activity [54]. Results of our study also demon-
strated reduced PON1 activity in rats fed with a SO diet. 
Furthermore, in the present study excesive consumption of soybean 
oil reduced TAC in plasma as consequence of elevated oxidative stress 
and high values of TOS. Hydrogen peroxide is one of the main compo-
nents of TOS and it oxidizes the enzyme MPO to a higher oxidation state, 
which further builds specific adducts in the cell with certain molecules. 
Actually, in the presence of nitrite and H2O2 myeloperoxidase is also 
able to form reactive nitrogen species, which can lead to further 
oxidative instability. Early study has demonstrated that MPO, PON1, 
and HDL-C form a functional complex in which PON1 partially inhibits 
the MPO activity, while MPO also partially inactivates the PON1 [53]. 
Also, serum MPO/PON1 ratio could be potencial indicator of HDL-C 
dysfunctionality [55]. On the other hand, there is no data about the 
effects of fat rich diet on MPO/PON1 relation contemporary. Our results 
clearly show that the highest increase in plasma MPO activity was 
observed only in SO group, evidenced with a drop in plasma PON 1 
activity. Therefore, the strong negative corelation between MPO and 
PON 1 indicates that the HDL-associated protein PON1 may be targeted 
for oxidative modification and functional inactivation by MPO. This 
data reveals the effects of different dietary compounds on MPO/PON1 
ratio and oxidative stability. This implies compromised antioxidative 
defense after unsaturated fat rich diet. 
The reductive reaction carried out by xanthine oxidase reduces ox-
ygen into a superoxide anion and produces uric acid. Hence, in our 
study, in the SO group, significantly increased level of uric acid is 
accompanied by an increase superoxide anion. Superoxide anion is a one 
of the major limitator of NO biosynthesis and bioavailability and can 
thus modify endothelial function. In this research, after SO diet, there is 
a disbalanced release of relaxing and contracting factors, NO2 and O2- , 
which can be accounted to increase systolic blood pressure, thereby 
contributing to further progression of vascular and organ damage. In 
that sense obtained increase in the ALTL, ASTL and LDHI2 after the SO 
diet appears to be logical. High levels of LDH indicate some form of 
tissue damage, whereas levels of ALT and AST are indicator of hepato-
cellular damage. Actually these enzymes are poor prognostic markers of 
the severity of liver injury [56]. 
Nutritional stress, such as high fat intake could lead to hepatic lipid 
accumulation [57]. However, if more than 10% percent of the liver’s 
weight is fat, then it is called a fatty liver (or liver in steatosis) [20]. 
Considering that is in normal conditions liver does not store triglyceride, 
recent studies suggest that normal liver may contain up to 5.5% tri-
glyceride and that a triglyceride content greater than 8% may be a 
reliable sign of pathologically fatty liver [58]. In our study, livers of 
soybean oil group and lard group contain 21.81% and 13.51%, respec-
tively, triglycerides that reveal strong hepatic steatosis. There are two 
concepts of steatosis confirmation: biochemical and histopathological. 
Keeping in mind apparentness of pathophysiology, biochemical concept 
has some advantages. Namely, some authors suggest that histopatho-
logical analysis of steatosis is not an adequate method due to a 
Fig. 7. Liver marker of inflammation: IL-6/interleukin-6 (A) and PTX3/pentraxin-3. 
(B) level in experimental groups. C-control, L-lard, SO-soybean oil group. Values are means ± SD; * ** , * * indicate p < 0.001, 0.01. 
Table 2 
Correlations between HDL-C function (characterized by PON1 and MPO activities), prooxidant-antioxidant balance (PAB), and levels of inflammatory biomarkers in 
the liver: IL-6 and PTX3. Marked correlations are significant at p < ,05000. N = 24.   
Plasma MPO Plasma PON Liver PAB Liver MPO Liver IL6 Liver PTX3 
Plasma MPO 1,0000 -,5980 ,6215 ,6494 ,4648 ,5819  
p = — p = ,002 p = ,001 p = ,001 p = ,022 p = ,003 
Plasma PON -,5980 1,0000 -,5895 -,5558 -,5270 -,6252  
p = ,002 p = — p = ,002 p = ,005 p = ,008 p = ,001 
Liver PAB ,6215 -,5895 1,0000 ,5146 ,6220 ,6346  
p = ,001 p = ,002 p = — p = ,010 p = ,001 p = ,001 
Liver MPO ,6494 -,5558 ,5146 1,0000 ,4610 ,7745  
p = ,001 p = ,005 p = ,010 p = — p = ,023 p = ,000 
Liver IL6 ,4648 -,5270 ,6220 ,4610 1,0000 ,4670  
p = ,022 p = ,008 p = ,001 p = ,023 p = — p = ,021 
Liver PTX3 ,5819 -,6252 ,6346 ,7745 ,4670 1,0000  
p = ,003 p = ,001 p = ,001 p = ,000 p = ,021 p = —  
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two-dimensional semi-quantitative nature susceptible to 
inter-individual visual estimation [59], therefore they recommend 
direct measurement of lipid in the liver as most reliable. In this regard, 
we noted that in our study soybean oil ingestion developed steatosis as 
evidenced with 218% and 230% increases in liver cholesterol and tri-
glyceride levels vs control, that is similarly as in the report of Echeverría 
et al. [57]. Another study has shown that mice fed with HFD had 
reduction in hepatic n-3 long-chain polyunsaturated fatty acids which 
induced deactivation of transcription factor peroxisome 
proliferator-activated receptor α (PPAR-α) and upregulated sterol reg-
ulatory element-binding protein- 1c (SREBP-1c). This alteration trigger 
FA oxidation and favouring de novo lipogenesis which can contribute to 
storage of triglyceride and liver steatosis [60]. Steatosis is associated 
with the onset of oxidative stress in the liver, as evidenced by significant 
changes in protein oxidation responses and 1.8-fold increase of lipid 
peroxidation. Increased level of both liver lipids and activity of antiox-
idant enzymes (SOD and CAT) may also contribute to the increased free 
oxygen radicals, leading to disturbed PAB and significantly increased 
activity of the MPO in the liver. Reactive oxygen species (ROS) over-
production is also an important factor of liver mitochondrial dysfunc-
tion. This dysfunction diminishes expression of the nuclear respiratory 
factor 1 (NRF-1) which deranges the expression of nuclear DNA and 
mtDNA encoded oxidative phosphorylation genes, thus decreases 
mitochondrial biogenesis [61] and reduces oxidative stability. The 
precise mechanism by which soybean oil intake produces liver injury is 
unknown, but it is believed that oxidative stress modulate this process. 
Most ingested lipids are incorporated in membrane phospholipids 
making them more susceptible to free radical attacks. This mainly occurs 
with UFAs which have unstable molecular bounds and therefore are 
more susceptible to oxidative stress and inflammation. This hypothesis 
is supported by our results, where SO diet induced significantly increase 
of hepatic MPO activity. Actually, in SO group, in states of increased 
inflammation via activity of MPO, lipid peroxidation product levels is 
also altered. MPO activity is linked to lipid peroxidation, which is a 
prominent characteristic of fatty livers, promoting activation of stellate 
cells and attraction of inflammatory cells [62,63]. 
MPO/HDL-C ratio in the liver was significantly elevated in SO group. 
Higher MPO/HDL-C level in this group was associated with increased 
level of inflammation factors: IL-6 and PTX3. These results suggest that 
dyslipidemia and nutritional oxidative stress deepenes inflammation in 
the liver after chronic ingestion of UFAs. On the other side, the metab-
olites of linoleic acid can mediate inflammation. Linoleic acid (n-6 
PUFAs), the main component of soybean oil, is metabolized to arach-
idonic acid which metabolites, eicosanoids, in large quantities can 
contribute to the formation of thrombus and atheroma, and induce 
pathological proliferation of cells [64]. Thus, a diet rich in n-6 PUFAs 
shifts the physiological state to one that is proinflammatory. 
Searching for the possible regulatory factors of inflammation in 
conditions of continuous high-fat intake, we can say that liver damage 
could be mediated by IL-6 and PTX3 after excessive UFAs intake. Liver 
PTX-3 was found significantly higher in the SO group than in C and L 
groups. Short components of this family are mainly produced by hepa-
tocytes in response to inflammation. In normal liver tissue hepatocytes 
are negative for PTX3 expression [65]. In the context of liver diseases 
levels of PTX3 were found to be elevated in chronic liver diseases: 
nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, liver 
cirrhosis, and chronic viral hepatitis [66–68]. Today, it is well known 
that increased caloric intake and reduced physical activity undoubtedly 
contribute to the prevalence of non-alcoholic fatty liver disease. It is an 
intra-hepatocellular accumulation of lipids (mainly triglycerides) that 
affects almost 30% of the Western world population. Several diagnostic 
panels have been developed to predict liver injuries. Although, liver 
biopsy and imaging studies demonstrate limited sensitivity while serum 
markers (like transaminase), platelet count, and high-sensitivity 
C-reactive protein has not been standardized for evaluating the 
severity of liver injuries. However, Yoneda et al. reported that PTX3 
levels are strongly correlated with the severity of liver disease [69]. In 
accordance with this finding, our results of high positive correlation 
between PAB and MPO, but IL-6 and PTX3 on the other, indicates a close 
connection between the molecular mechanisms that regulate nutritional 
stress and inflammation in this experimental design. Because of this we 
think that PTX-3 could be a useful inflammatory marker of liver damage 
after chronic excessive high-fat intake. 
In conclusion, contrary to expectation, our study shows that exces-
sive consumption of the soybean oil is more inflammogenic than lard. By 
correlation analysis we confirmed the existence of association between 
nutritional oxidative stress-induced HDL-C dysfunction and inflamma-
tion after prolonged soybean oil consumption. These results give a new 
insight on the negative impact of excessive soybean oil diet on cardio-
vascular system by compromising oxidative stability and inducing 
inflammation. Therefore, we suggested the use of different diet com-
positions and different fatty acids as the goals of the future studies in 
order to clarify safety and healthy nutrition as well as creative a food 
environment where healthy foods are accessible, affordable, and desir-
able as the main precursor of reduction of cardiovascular disease. 
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Schiavon, Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis, 
Ann. Hepatol. 16 (2017) 780–787, https://doi.org/10.5604/01.3001.0010.2789. 
[68] J. Gorka-Dynysiewicz, M. Pazgan-Simon, J. Zuwala-Jagiello, Pentraxin 3 detects 
clinically significant fibrosis in patients with chronic viral Hepatitis C, Biomed. Res 
Int. 2019 (2019), 2639248, https://doi.org/10.1155/2019/2639248. 
[69] M. Yoneda, T. Uchiyama, S. Kato, H. Endo, K. Fujita, K. Yoneda, H. Mawatari, 
H. Iida, H. Takahashi, H. Kirikoshi, M. Inamori, Y. Nozaki, N. Kobayashi, 
K. Kubota, S. Saito, S. Maeyama, M. Sagara, H. Aburatani, T. Kodama, A. Nakajima, 
Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH), BMC 
Gastroenterol. 8 (2008) 53, https://doi.org/10.1186/1471-230X-8-53. 
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